Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.
Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.
复制标题
淋巴瘤分类更新：T细胞淋巴瘤，霍奇金淋巴瘤和组织细胞/树突状细胞肿瘤。
DOI：
10.1080/17474086.2017.1281122
复制
发表时间：
2017-03
影响因子：
2.8
通讯作者：
Feldman AL
中科院分区：
文献类型：
--
作者：
Jiang M;Bennani NN;Feldman AL
淋巴瘤的分类基于正常的对应物，或细胞的起源，从它们产生。由于淋巴细胞具有生理免疫功能，其随谱系和分化阶段而变化，因此由这些正常淋巴样群体产生的淋巴瘤的分类是复杂的。最近的基因组数据对这种复杂性做出了更多的贡献。淋巴瘤分类遵循世界卫生组织（WHO）系统，该系统反映了国际共识，并基于病理，遗传和临床因素。本综述重点关注T细胞淋巴瘤、霍奇金淋巴瘤、组织细胞和树突状细胞肿瘤的分类，总结了2016年修订WHO分类中反映的变化。这些变化对血液学家和其他护理这些疾病患者的临床医生至关重要。淋巴瘤分类是一个不断发展的领域，需要对淋巴瘤形成的新的临床、病理和分子理解做出反应。在本次审查所涵盖的实体中，2016年修订的WHO分类特别影响T细胞淋巴瘤，包括T滤泡辅助细胞来源的淋巴瘤的新伞形分类以及对惰性T细胞淋巴瘤和淋巴增生性疾病的不断认识。
Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional depth to this complexity. Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. The present review focuses on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic and dendritic cell neoplasms, summarizing changes reflected in the 2016 revision to the WHO classification. These changes are critical to hematologists and other clinicians who care for patients with these disorders. Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revisions in the WHO classification particularly impact T-cell lymphomas, including a new umbrella category of T-follicular helper cell-derived lymphomas and evolving recognition of indolent T-cell lymphomas and lymphoproliferative disorders.
登录
查看更多内容
影响因子：
28.2
作者：
Diamond EL;Durham BH;Haroche J;Yao Z;Ma J;Parikh SA;Wang Z;Choi J;Kim E;Cohen-Aubart F;Lee SC;Gao Y;Micol JB;Campbell P;Walsh MP;Sylvester B;Dolgalev I;Aminova O;Heguy A;Zappile P;Nakitandwe J;Ganzel C;Dalton JD;Ellison DW;Estrada-Veras J;Lacouture M;Gahl WA;Stephens PJ;Miller VA;Ross JS;Ali SM;Briggs SR;Fasan O;Block J;Héritier S;Donadieu J;Solit DB;Hyman DM;Baselga J;Janku F;Taylor BS;Park CY;Amoura Z;Dogan A;Emile JF;Rosen N;Gruber TA;Abdel-Wahab O
通讯作者：
Abdel-Wahab O
影响因子：
45.3
作者：
Diehl, V;Sextro, M;Stein, H
通讯作者：
Stein, H
影响因子：
20.3
作者：
de Leval, Laurence;Rickman, David S.;Gaulard, Philippe
通讯作者：
Gaulard, Philippe
DOI：
10.1016/j.beha.2013.04.007
发表时间：
2013-03
期刊：
Best practice & research. Clinical haematology
影响因子：
--
作者：
Bajor-Dattilo EB;Pittaluga S;Jaffe ES
通讯作者：
Jaffe ES
影响因子：
5.6
作者：
Aladily, Tariq N.;Medeiros, L. Jeffrey;Miranda, Roberto N.
通讯作者：
Miranda, Roberto N.